Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation-Reference-Cited by-同舟云学术

Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation

Published:2016-02-03 Issue:9 Volume:18 Page:1319-1327
ISSN:1099-5129
Container-title:Europace
language:en
Short-container-title:Europace

Author:

Korenstra Jennie,Wijtvliet E. Petra J.,Veeger Nic J.G.M.,Geluk Christiane A.,Bartels G. Louis,Posma Jan L.,Piersma-Wichers Margriet,Van Gelder Isabelle C.,Rienstra Michiel,Tieleman Robert G.

Publisher

Oxford University Press (OUP)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference20 articles.

1. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA)

2. Guidelines for the management of atrial fibrillation

3. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis

4. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

5. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Left atrial appendage occlusion after thromboembolic events or left atrial appendage sludge during anticoagulation therapy: Is two better than one? Real‐world experience from a tertiary care hospital;Journal of Arrhythmia;2023-03-11

2. RISK FACTORS, ORAL ANTICOAGULANTS-BASED THERAPEUTICAL APPROACHES AND COMORBIDITIES IN ATRIAL FIBRILLATION: 4216 PATIENTS FROM A ROMANIAN HOSPITAL;FARMACIA;2022-06-26

3. References;Genesis, Pathophysiology and Management of Venous and Lymphatic Disorders;2022

4. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective;Clinical Drug Investigation;2021-02-15

5. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy;Journal of Clinical Medicine;2020-12-28